Current state of, prospects for, and obstacles to mRNA vaccine development

Aljabali, Alaa A. A.; Bashatwah, Rasha M.; Obeid, Mohammad A.; Mishra, V.; Mishra, Yachana; Serrano‐Aroca, Ángel; Lundström, Kenneth; Tambuwala, Murtaza M.

doi:10.1016/j.drudis.2022.103458

Cited by 12 publications

(10 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 This prompted us to hypothesize that as ODNs grow, their solubility may decrease, and the reactions may become less efficient. Our success in the present study may inspire the use of PEGylation to improve the efficiency of unmodified DNA and RNA synthesis, which can have a high impact on projects in areas such as synthetic biology, 14 protein engineering, 15 mRNA vaccine development 16 and DNA computer digital data storage 17 in which the availability of long DNA and RNA is crucial for success. In addition, the synthesis of ODNs containing more than one 4acC modification is remarkable.…”

Section: Resultsmentioning

confidence: 90%

PEGylated Dmoc phosphoramidites for sensitive oligodeoxynucleotide synthesis

Chillar,

Yin,

Apostle

et al. 2023

Org. Biomol. Chem.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 90%

PEGylated Dmoc phosphoramidites for sensitive oligodeoxynucleotide synthesis

Chillar,

Yin,

Apostle

et al. 2023

Org. Biomol. Chem.

View full text Add to dashboard Cite

show abstract

“…Due to limitations such as stability, intrinsic toxicity, and poor distribution, the applicability of RNA vaccines was initially restricted compared to other platforms [4]. However, the application of chemical modifications, codon optimization, and integration of carrier molecules has broadened its usefulness and sparked significant interest in the production of vaccines against infectious [5], autoimmune [11], and neoplastic diseases [12] (Figure 1).…”

Section: Rna Vaccines and Delivery Systemsmentioning

confidence: 99%

“…Within this scenario, the mRNA-based vaccine production strategy proved to be a safe, fast, and effective alternative. Primarily developed decades ago, RNA vaccines took a long time to be widely employed due to inherent problems such as low stability, excessive immunostimulation, and low efficacy in some trials [3,4]. However, with advances in sequence modifications, such as codon optimization, chemical modifications, and the use of carrier molecules, the possibility of its use in clinical applications has grown [5].…”

Section: Introductionmentioning

confidence: 99%

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Silva¹,

Souza²,

Macêdo³

et al. 2023

Preprint

View full text Add to dashboard Cite

In the last decades, technological advances related to RNA manipulation enabled and expanded its application in vaccine development. This approach comprises synthetic single-stranded mRNA molecules that direct the translation of the antigen responsible for activating the desired immune response. The success of RNA vaccines depends on the delivery vehicle employed. Among the systems, yeasts emerge as a new approach to a natural delivery platform. The presence of β-glucans and mannans in its wall is responsible for the adjuvant action of this system. Yeasts are already employed to deliver protein antigens, with success and efficacy demonstrated through pre-clinical and clinical trials. Yeast β-glucan capsules, microparticles, and nanoparticles are capable of modulating host immune responses and have a high capacity to carry RNA and small molecules, with bioavailability upon oral immunization and with targeting to receptors present in anti-gen-presenting cells (APCs). Besides, yeasts are interesting vehicles for the protection and specific delivery of therapeutic vaccines based on shRNA or dsRNA. In this review, we present an overview of the attributes of yeast or its derivatives for the delivery of RNA-based vaccines, discussing their current challenges and prospects for using this promising strategy.

show abstract

“…mRNA vaccines are more temperature-sensitive than traditional vaccines, given RNA’s inherent instability. External factors such as temperature, pH and enzyme activity can induce rapid RNA degradation [ 74 , 75 ]. Without proper stabilizers, mRNA molecules may be swiftly recognized and cleared by the body’s immune system before entering the target cells [ 76 , 77 ].…”

Section: Adjuvantmentioning

confidence: 99%

Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies

Wang,

Fang

et al. 2023

Vaccines

View full text Add to dashboard Cite

Tuberculosis (TB) remains a global infectious disease primarily transmitted via respiratory tract infection. Presently, vaccination stands as the primary method for TB prevention, predominantly reliant on the Bacillus Calmette–Guérin (BCG) vaccine. Although it is effective in preventing disseminated diseases in children, its impact on adults is limited. To broaden vaccine protection, efforts are underway to accelerate the development of new TB vaccines. However, challenges arise due to the limited immunogenicity and safety of these vaccines, necessitating adjuvants to bolster their ability to elicit a robust immune response for improved and safer immunization. These adjuvants function by augmenting cellular and humoral immunity against M. tuberculosis antigens via different delivery systems, ultimately enhancing vaccine efficacy. Therefore, this paper reviews and summarizes the current research progress on M. tuberculosis vaccines and their associated adjuvants, aiming to provide a valuable reference for the development of novel TB vaccines and the screening of adjuvants.

show abstract

Current state of, prospects for, and obstacles to mRNA vaccine development

Cited by 12 publications

References 126 publications

PEGylated Dmoc phosphoramidites for sensitive oligodeoxynucleotide synthesis

PEGylated Dmoc phosphoramidites for sensitive oligodeoxynucleotide synthesis

RNA Vaccines: Yeast as a Novel Antigen Vehicle

Enhancing TB Vaccine Efficacy: Current Progress on Vaccines, Adjuvants and Immunization Strategies

Contact Info

Product

Resources

About